1292289-46-3

Usage

Uses

Used in Pharmaceutical Industry:
(S)-4-(Aminomethyl)pyrrolidin-2-one is used as a chiral building block for the synthesis of pharmaceuticals, enabling the production of chiral drug molecules with enhanced stereoselectivity and efficacy.
Used in Agrochemical Industry:
(S)-4-(Aminomethyl)pyrrolidin-2-one is used as a chiral building block for the synthesis of agrochemicals, contributing to the development of more effective and selective crop protection agents.
Used in Organic Synthesis:
(S)-4-(Aminomethyl)pyrrolidin-2-one is used as a reagent in organic synthesis, facilitating the creation of complex molecules with improved stereochemical control.
Used in Catalysis:
(S)-4-(Aminomethyl)pyrrolidin-2-one is studied for its potential applications in catalysis, leveraging its unique structural and chemical properties to enhance reaction efficiency and selectivity.
Used in Material Science:
(S)-4-(Aminomethyl)pyrrolidin-2-one is explored for its potential use in material science, where its unique properties may contribute to the development of novel materials with specific characteristics and applications.

Upstream product

• 173340-22-2 (4S)-4-(aminomethyl)-1-[(1R)-1-phenylethyl]pyrrolidin-2-one 
• 97-65-4 2-methylenesuccinic acid 
• 99735-43-0 (3R)-1-((R)-1-phenylethyl)-5-oxo-3-pyrrolidinecarboxylic acid 
• 1292289-47-4 (3R)-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carbonitrile 
• 173340-21-1 (3R)-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxamide 
• 190957-22-3 (4R,1'R)-1-(1'-phenylethyl)-4-hydroxymethylpyrrolidin-2-one 
• 1319736-72-5 C₂₁H₁₆Cl₄N₂O₃ 
• 1319736-73-6 C₁₃H₈Cl₄N₂O₃ 

Downstream Products

• 1319738-00-5 (S)-4-((7-(3,4,5-trimethoxyphenyl)-1,6-naphthyridine-5-ylamino)methyl)pyrrolidine-2-one 

Relevant academic research and scientific papers

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among —O—R3 or —NR3R4,R3 is C1-6-alkyl which is substituted by R5 and R6,R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, —C1-6-alkylen-O—C1-3-alkyl, C1-3-haloalkyl,R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond andwherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C1-3-alkyl, —C1-3-haloalkyl, —O—C1-3-alkyl, —C1-3-alkanol and halogen,and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.

Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826

A compound of formula (I): and pharmaceutically-acceptable salts thereof, wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS

The invention relates to new substituted naphthyridines of formula (1), as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among -O-R3 or -NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6 R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, -C1-6-alkylen-O-C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and Formula (I) is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, -C1-3-alkyl, -C1-3-haloalkyl, -O-C1-3-alkyl, -C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.